Drug Profile
Research programme: atherosclerosis therapeutics - KineMed/Merck
Latest Information Update: 24 Aug 2011
Price :
$50
*
At a glance
- Originator KineMed; Merck AG
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atherosclerosis
Most Recent Events
- 24 Aug 2011 No development reported - Preclinical for Atherosclerosis in USA (unspecified route)